BGNE BeiGene, Ltd.: Forward P/S Multiple

beigene.com (BGNE) - corporate logo

BeiGene, Ltd. (BGNE) leverages a broad presence across the US, Europe, and China to minimize regulatory risks. The professional management of John Euler ensures successful global expansion and financial stability. The brand's strong pricing power confirms its status as an oncology innovator. This chart of the company's projected P/S is available in the GURU.Markets system, where 5.50 determines the latest market demand valuation metric.

beigene.com - BGNE Projected Price to Revenue (period 07/04/2022 - 11/15/2026)

BeiGene, Ltd. - analytical breakdowns and key metrics (BGNE)

- current price and projected stock value:
Initial company analysis:BeOne Medicines (BGNE)
Original product of BeiGene Ltd

The forward P/S ratio determines the market value of a business relative to expected revenue, allowing investors to assess the premium paid for future earnings without reporting delays. By analyzing the forward P/S trend, one can understand how BeiGene, Ltd. (BGNE) expenditures on environmental plant modernization and the implementation of green technologies impact the long-term capitalization and investment attractiveness of this biotech behemoth.

Key competitors

Forward P/S Multiple ONC (BeiGene Oncology)|Forward P/S Multiple Halozyme Corp HALO|RVMD: Forward Price-to-Revenue Multiple|Ascentage Pharma Group (AAPG) - Forward Price-to-Revenue Multiple|CG Oncology Therapeutics (CGON) - Price-to-Projected Revenue Ratio|Projected Price to Revenue UroGen Pharma URGN|Price-to-Projected Revenue Ratio Bicara Bio|Market Cap to Future Revenue Ratio Personalis Genomics PSNL|Forward P/S Multiple ERAS|Price to Expected Revenue Ratio DCTH|Y-mAbs Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Aura Biosciences Inc (AURA)|CADL: Forward Price-to-Revenue Multiple|Forward Price to Sales ARAY (Accuray Inc.)|SLS: Forward P/S Multiple|ACTU: Price to Expected Revenue Ratio|CTOR (Citius Oncology Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio tuhurabio.com HURA|Forward P/S Multiple TARA|FATE: Future Price to Revenue|Forward P/S Multiple WHWK (Aadi Bioscience)|TCRX (TScan) - Future Price to Revenue|Champions Oncology, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio XBiotech Inc XBIT|CVM: Forward P/S Multiple|OSTX - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Radiopharm Theranostics Limited|Forward P/S Multiple artivabio.com|Forward Price-to-Revenue Multiple ANL (Adlai Nortye Limited)|Veru - Market Cap to Projected Revenue|Tempest Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio xiliotx.com (XLO)|Renovaro - Forward P/S Multiple|Mural Oncology (MURA) - Forward Price-to-Revenue Multiple|KAPA: Forward P/S Multiple|OKUR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio CytoMed Therapeutics Limited|CRIS: Forward Price to Sales|Forward P/S Multiple APLM|Forward P/S Multiple tharimmune.com (THAR)|Advanced Biomed Corp - Forward Price-to-Revenue Multiple|Forward Price to Sales GNPX|Calidi Biotherapeutics, Inc. - Forward P/S Multiple|Sunshine Biopharma (SBFM) - Forward Price-to-Revenue Multiple|XBIO: Forward P/S Multiple|SLRX - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple PPBT|Forward P/S Multiple American Oncology Network|Price-to-Projected Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|Forward Price-to-Revenue Multiple Elevation Oncology, Inc. ELEV|Forward P/S Multiple ICAD (iCAD Inc.)|IKNA - Forward Price-to-Revenue Multiple|NTBL: Forward Price-to-Revenue Multiple|viracta.com (VIRX) - Forward Price-to-Revenue Multiple|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Corp (NAYA) - Forward P/S Multiple|AAPGV (Ascentage) - Forward P/S Multiple